# EDGAR Filing Document

**Accession Number:** 0001082554
**File Stem:** 0001104659-26-069549
**Filing Date:** 2026-6
**Character Count:** 5729
**Document Hash:** 8416a6a0d4a790d51a40d970d911942f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-069549.hdr.sgml**: 20260602

**ACCESSION NUMBER**: 0001104659-26-069549

**CONFORMED SUBMISSION TYPE**: SD

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260602

**DATE AS OF CHANGE**: 20260602

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UNITED THERAPEUTICS Corp
- **CENTRAL INDEX KEY:** 0001082554
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 521984749
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SD
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-26301
- **FILM NUMBER:** 261057502

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 SPRING ST
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910
- **BUSINESS PHONE:** 3016089292

**MAIL ADDRESS:**
- **STREET 1:** 1000 SPRING ST
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** UNITED THERAPEUTICS CORP
- **DATE OF NAME CHANGE:** 19990324

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM SD**

**SPECIALIZED DISCLOSURE REPORT**

**United Therapeutics Corporation**

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-26301** | **52-1984749** |
| (State or Other | (Commission | (I.R.S. Employer |
| Jurisdiction of | File Number) | Identification Number) |
| Incorporation or Organization) |  |  |

---

---

| | |
|:---|:---|
| **1000 Spring Street** |  |
| **Silver Spring, MD** | **20910** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

James Edgemond, (301) 608-9292

(Name and telephone number, including area code, of the

person to contact in connection with this report)

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

⌧ Rule 13p-1 under the Securities Exchange
Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025.

◻ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ______.

**Item 1.01 Conflict Minerals Disclosure and Report.**

United Therapeutics Corporation (**UT**) is committed to social responsibility in the supply chain of its materials, including considerations and requirements relating to the environment, safety, health, and human rights. This includes efforts to comply with rules and regulations promulgated by the U.S. Securities and Exchange Commission to implement Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the **Conflict Mineral Rules**). These rules require UT to conduct a reasonable country of origin inquiry that is reasonably designed to determine whether Conflict Minerals (defined below) necessary to the functionality or production of products manufactured or contracted to be manufactured by UT originated in Covered Countries (defined below) or came from recycled or scrap sources.

The Conflict Mineral Rules define **Conflict Minerals** as cassiterite, columbite-tantalite, gold, wolframite, and their derivatives (which are limited to tin, tantalum, and tungsten). **Covered Countries** is defined as the Democratic Republic of the Congo and its adjoining countries.

In accordance with the Conflict Mineral Rules, UT has determined that it has two products that contain Conflict Minerals (the **Relevant Products**). UT has conducted a good faith, reasonable country of origin inquiry (as described below) and determined that certain Conflict Minerals in the Relevant Products may have originated in Covered Countries. However, based on supplier responses and due diligence, UT has no reason to believe that such Conflict Minerals were sourced from smelters or refiners that are not compliant with the Responsible Minerals Initiative (**RMI**) or equivalent industry standards. Therefore, UT is not required to provide a conflict minerals report concerning the Relevant Products.

UT contracts to manufacture the Relevant Products and does not directly purchase Conflict Minerals included in the products. UT's reasonable country of origin inquiry included an examination of the bill of materials and approved supplier list for the Relevant Products. Based on that review, UT conducted a comprehensive inquiry of a total of 100 companies, representing all UT's direct suppliers relating to the Relevant Products and their respective first and second-tier component suppliers. UT requested each supplier to provide a written statement regarding its use of Conflict Minerals to determine whether any Conflict Minerals originating in Covered Countries (and not from scrap or recycled sources) were incorporated into the Relevant Products. UT received responses from all of these suppliers, and, based on their responses, had no reason to believe Conflict Minerals necessary to the functionality or production of the Relevant Products were sourced from smelters or refiners that are non-compliant with the RMI.

<u>Conflict Minerals Disclosure</u>

 

*This Conflict Minerals Disclosure is publicly available on UT's website, located at <u>http://ir.unither.com/corporate-governance</u>.*

 

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

---

| | | |
|:---|:---|:---|
|  | UNITED THERAPEUTICS CORPORATION | UNITED THERAPEUTICS CORPORATION |
| Date: June 2, 2026 | By: | /s/ John S. Hess, Jr. |
|  | Name: | John S. Hess, Jr. |
|  | Title: | EVP, Deputy General Counsel |

---